Axsome Therapeutics, Inc. (AXSM)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$305.1M
Cash & Equivalents
$20.7M
Quarterly Burn Rate
44 mo
Est. Cash Runway
$12,068M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (2 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
BUPROPION HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE
AUVELITY |
APPROVED | ADHD, Agitation, Agitation in Patients With Dementia of the Alzheimer's Type, Agitation, Psychomotor, Agitation,Psychomotor, Alzheimer Disease, Binge-Eating Disorder, Cataplexy, Cataplexy Narcolepsy, Complex Regional Pain Syndrome, Depression, Excessive Daytime Sleepiness, Excessive Daytime Somnolence, Excessive Sleepiness, Fibromyalgia, Impaired Cognitive Function, Insomnia, Major Depressive Disorder, Major Depressive Disorder (MDD), Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms, Migraine, Multiple Sclerosis, Multiple Sclerosis Fatigue, Narcolepsy, Nicotine Dependence, Obstructive Sleep Apnea, Osteoarthritis, Knee, Postpartum, Pregnant Women and Their Offspring, Reflex Sympathetic Dystrophy, Shift-work Disorder, Smoking Cessation, Smoking, Cigarette, Treatment Resistant Depression, Treatment Resistant Major Depressive Disorder |
|
MELOXICAM, RIZATRIPTAN BENZOATE
SYMBRAVO |
APPROVED | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.